CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 5, 1999, Pages 528-534

  Tanigawara, Yusuke ^b   Aoyama, Nobuo ^d   Kita, Tomoko ^d   Shirakawa, Katsuro ^d   Komada, Fusao ^c   Kasuga, Masato ^d   Okumura, Katsuhiko ^a  

^a KOBE UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c JOSAI UNIVERSITY   (Japan)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH NITRATE; CLARITHROMYCIN; CYTOCHROME P450; FAMOTIDINE; NIZATIDINE; OMEPRAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; DIAGNOSTIC VALUE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME ASSAY; GASTRITIS; GENOTYPE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT PLANNING;

EID: 0000334112     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0009-9236(99)70017-2     Document Type: Article

References (29)

1. 1. Labenz J, Gyenes E, Ruhl GH, Borsch G. Amoxycillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomised and controlled study. Gut 1993; 34:1167-70.
2. 2. Logan RPH, Gummett PA, Schaufelberger HD, Greaves RPFH, Mendelson GM, Walker MM, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994;35:323-6.
3. 3. Bazzoli F, Zagari RM, Fossi S, Pozzato P, Alampi G, Simoni P, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol 1994;6:773-7.
4. 4. Dixxin JS. Helicobacter pylori eradication: unraveling the facts. Scand J Gastroenterol 1995;30:48-62.
5. 5. Labenz J, Stolte M, Blum AL, Jorias I, Sollbohmer M, Bertrams J, et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995;37:39-43.
6. 6. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole: a gastric proton pump inhibitor on pentagastrin stimulated acid secretion in man. Gut 1983; 24:270-6.
7. 7. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4-hydroxylation status. Clin Pharmacol Ther 1995;58:143-54.
8. 8. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor melabolizers of S-mephenytoin 4-hydroxylalion recruited from an Oriental population. J Pharmacol Exp Ther 1992;262:1195-202.
9. 9. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995;39:511-8.
10. m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996;59:647-53.
11. 11. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
12. 12. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
13. 13. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-99.
14. 14. Okumura K, Kita T, Chikazawa S, Komada F, Iwakawa S, Tanigawara Y. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin Pharmacol Ther 1997;61:509-17.
15. 15. Tanigawara Y, Kita T, Aoyama N, Shirakawa N, Komada F, Kasuga M, et al. Relationships between P450 genotype and efficacy of omeprazole for the treatment of H pylori infection [abstract]. Gastroenterology 1997;112:A308.
16. 16. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129: 1027-30.
17. 17. Lind T, Zanten SV, Unge P, Spiller R, Bayerdorffer E, O'Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1996;1:138-44.
18. 18. Vatsis KP, Weber WW. Human N-acetyltransferases. In: Kauffman FC, editor: Conjugation-deconjugation reactions in drug metabolism and toxicity, vol 112. Berlin: Springer-Verlag; 1994. p. 109-30.
19. 19. Bertilsson L. Geographical-interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
20. 20. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
21. 21. Graham DY, Lew GM, Klein PD, Evans DC, Evans DJ Jr, Saeed ZA, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer: a randomized, controlled study. Ann Intern Med 1992;116:705-8.
22. 22. Loft S, Otton SV, Lennard MS, Tucker GT, Poulsen HE. Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol 1991;41:1127-34.
23. 23. Mastrandrea V, Ripa S, La Rosa F, Tarsi R. Human intravenous and intramuscular pharmacokinetics of amoxicillin. Int J Clin Pharmacol Res 1984;4:209-12.
24. 2-blocker: its metabolism and disposition in man. Drag Metab Dispos 1985;14:175-82.
25. 25. Yeh KC, Chremos AN, Lin JH, Constanzer ML, Kanovsky SM, Hucker HB, et al. Single dose pharmacokinetics and bioavailability of famotidine in man: results of multicenter collaborative studies. Biopharm Drug Dispos 1987;8:549-60.
26. 26. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol 1994;29:16-23.
27. 27. Cederbrant G, Kahlmeter G, Schalen C, Kamme C. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother 1994;34:1025-9.
28. 28. Goddard AF, Jessa MJ, Barrett DA, Shaw N. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996;111:358-67.
29. 29. Debets-Ossenkopp YJ, Sparrius M, Kusters JG, Kolkman JJ, Vandenbroucke-Grauls CMJE. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett 1996;142:37-42.